FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2788868093> ?p ?o ?g. }

• W2788868093 endingPage "436" @default.
• W2788868093 startingPage "424" @default.
• W2788868093 abstract "Changes in NAD metabolism play an important role in the aging process and in the pathogenesis of several diseases. ‘NAD boosting’ therapy can promote increases in longevity and healthspan in animal models of aging, accelerated aging, and age-related disease. CD38 is one of the main NAD-degrading enzymes in mammalian tissues, and plays a key role in age-related NAD decline. CD38 is a druggable target in the therapy of human cancers. Inhibition of CD38 with small molecules or monoclonal antibodies can decrease NADase activity and boost cellular NAD levels. Recent reports indicate that intracellular NAD levels decline in tissues during chronological aging, and that therapies aimed at increasing cellular NAD levels could have beneficial effects in many age-related diseases. The protein CD38 (cluster of differentiation 38) is a multifunctional enzyme that degrades NAD and modulates cellular NAD homeostasis. At the physiological level, CD38 has been implicated in the regulation of metabolism and in the pathogenesis of multiple conditions including aging, obesity, diabetes, heart disease, asthma, and inflammation. Interestingly, many of these functions are mediated by CD38 enzymatic activity. In addition, CD38 has also been identified as a cell-surface marker in hematologic cancers such as multiple myeloma, and a cytotoxic anti-CD38 antibody has been approved by the FDA for use in this disease. Although this is a remarkable development, killing CD38-positive tumor cells with cytotoxic anti-CD38 antibodies is only one of the potential pharmacological uses of targeting CD38. The present review discusses the biology of the CD38 enzyme and the current state of development of pharmacological tools aimed at CD38, and explores how these agents may represent a novel approach for treating human conditions including cancer, metabolic disease, and diseases of aging. Recent reports indicate that intracellular NAD levels decline in tissues during chronological aging, and that therapies aimed at increasing cellular NAD levels could have beneficial effects in many age-related diseases. The protein CD38 (cluster of differentiation 38) is a multifunctional enzyme that degrades NAD and modulates cellular NAD homeostasis. At the physiological level, CD38 has been implicated in the regulation of metabolism and in the pathogenesis of multiple conditions including aging, obesity, diabetes, heart disease, asthma, and inflammation. Interestingly, many of these functions are mediated by CD38 enzymatic activity. In addition, CD38 has also been identified as a cell-surface marker in hematologic cancers such as multiple myeloma, and a cytotoxic anti-CD38 antibody has been approved by the FDA for use in this disease. Although this is a remarkable development, killing CD38-positive tumor cells with cytotoxic anti-CD38 antibodies is only one of the potential pharmacological uses of targeting CD38. The present review discusses the biology of the CD38 enzyme and the current state of development of pharmacological tools aimed at CD38, and explores how these agents may represent a novel approach for treating human conditions including cancer, metabolic disease, and diseases of aging. second messengers involved in calcium signaling. an enzyme that catalyzes the conversion of NAD into its cyclic analog cADPR and nicotinamide. an enzymatic activity that leads to the degradation of NAD irrespective of the products. enzyme catalyzing the cleavage of the glycosidic bond between the nicotinamide and ribose moieties of NAD. This leads to the degradation of NAD and formation of the products ADPR and nicotinamide. molecules that can be used by cells and tissues to make NAD. They include nicotinamide and vitamin B3 derivatives such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). NAD-dependent deacetylases involved in the control of metabolism, healthspan, and aging. In mammals there are seven sirtuins (SIRT1–7)." @default.
• W2788868093 created "2018-03-06" @default.
• W2788868093 creator A5034202693 @default.
• W2788868093 creator A5046379137 @default.
• W2788868093 creator A5057234650 @default.
• W2788868093 creator A5068170261 @default.
• W2788868093 creator A5081213250 @default.
• W2788868093 date "2018-04-01" @default.
• W2788868093 modified "2023-10-11" @default.
• W2788868093 title "The Pharmacology of CD38/NADase: An Emerging Target in Cancer and Diseases of Aging" @default.
• W2788868093 cites W1525866552 @default.
• W2788868093 cites W1560040722 @default.
• W2788868093 cites W1763778697 @default.
• W2788868093 cites W1847534405 @default.
• W2788868093 cites W1850228883 @default.
• W2788868093 cites W1894322524 @default.
• W2788868093 cites W1902692042 @default.
• W2788868093 cites W1938402249 @default.
• W2788868093 cites W1956577976 @default.
• W2788868093 cites W1966100607 @default.
• W2788868093 cites W1966292963 @default.
• W2788868093 cites W1979845008 @default.
• W2788868093 cites W1989674299 @default.
• W2788868093 cites W2008764263 @default.
• W2788868093 cites W2012043504 @default.
• W2788868093 cites W2013844116 @default.
• W2788868093 cites W2020855398 @default.
• W2788868093 cites W2032360023 @default.
• W2788868093 cites W2038011036 @default.
• W2788868093 cites W2044697772 @default.
• W2788868093 cites W2045089496 @default.
• W2788868093 cites W2050376414 @default.
• W2788868093 cites W2052639550 @default.
• W2788868093 cites W2054537854 @default.
• W2788868093 cites W2057770806 @default.
• W2788868093 cites W2062200458 @default.
• W2788868093 cites W2062481845 @default.
• W2788868093 cites W2070162988 @default.
• W2788868093 cites W2070560938 @default.
• W2788868093 cites W2071555363 @default.
• W2788868093 cites W2072259475 @default.
• W2788868093 cites W2072356438 @default.
• W2788868093 cites W2076252987 @default.
• W2788868093 cites W2082393205 @default.
• W2788868093 cites W2100548432 @default.
• W2788868093 cites W2101580126 @default.
• W2788868093 cites W2110720693 @default.
• W2788868093 cites W2112866277 @default.
• W2788868093 cites W2119798638 @default.
• W2788868093 cites W2123895023 @default.
• W2788868093 cites W2127483170 @default.
• W2788868093 cites W2129155846 @default.
• W2788868093 cites W2141502099 @default.
• W2788868093 cites W2167665292 @default.
• W2788868093 cites W2171748049 @default.
• W2788868093 cites W2225399376 @default.
• W2788868093 cites W2239653845 @default.
• W2788868093 cites W2276800670 @default.
• W2788868093 cites W2284984697 @default.
• W2788868093 cites W2296761075 @default.
• W2788868093 cites W2298455799 @default.
• W2788868093 cites W2322945529 @default.
• W2788868093 cites W2333241266 @default.
• W2788868093 cites W2343193821 @default.
• W2788868093 cites W2400466055 @default.
• W2788868093 cites W2423823537 @default.
• W2788868093 cites W2427895239 @default.
• W2788868093 cites W2432789362 @default.
• W2788868093 cites W2439803058 @default.
• W2788868093 cites W2483544500 @default.
• W2788868093 cites W2537034621 @default.
• W2788868093 cites W2537387853 @default.
• W2788868093 cites W2546015443 @default.
• W2788868093 cites W2548864808 @default.
• W2788868093 cites W2560056218 @default.
• W2788868093 cites W2575657372 @default.
• W2788868093 cites W2586021575 @default.
• W2788868093 cites W2588300742 @default.
• W2788868093 cites W2592248309 @default.
• W2788868093 cites W2592892973 @default.
• W2788868093 cites W2612430336 @default.
• W2788868093 cites W2738253488 @default.
• W2788868093 cites W2745226153 @default.
• W2788868093 cites W2764340845 @default.
• W2788868093 cites W2766732883 @default.
• W2788868093 cites W2767256995 @default.
• W2788868093 cites W2767761069 @default.
• W2788868093 doi "https://doi.org/10.1016/j.tips.2018.02.001" @default.
• W2788868093 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5885288" @default.
• W2788868093 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29482842" @default.
• W2788868093 hasPublicationYear "2018" @default.
• W2788868093 type Work @default.
• W2788868093 sameAs 2788868093 @default.
• W2788868093 citedByCount "141" @default.
• W2788868093 countsByYear W27888680932018 @default.
• W2788868093 countsByYear W27888680932019 @default.
• W2788868093 countsByYear W27888680932020 @default.
• W2788868093 countsByYear W27888680932021 @default.

• next